Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BBS-Bioactive Bone Substitutes Plc: Managers' Transactions

BBS-Bioactive Bone Substitutes Oyj
Posted on: 21 Feb 18

BBS-BIOACTIVE BONE SUBSTITUTES PLC MANAGERS' TRANSACTIONS 21.02.2018 AT 20:30

BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Jarmo Halonen

Position: Member of the Board/Deputy member

Issuer: BBS-Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20180221184849_3

____________________________________________

Transaction date: 2018-02-18

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 10,800 Unit price: 5.5 EUR

Aggregated transactions

(1): Volume: 10,800 Volume weighted average price: 5.5 EUR

Further enquiries:

Pekka Jalovaara, CEO,
tel. +358 50 5529275, e-mail: pekka.jalovaara@bbs-artebone.fi  

Hannu Säynäjäkangas, CFO,
tel. +358 40 5021092, e-mail: hannu.saynajakangas@bbs-artebone.fi

Hanna Tölli, Production Manager,
tel. +358 40 0953131, e-mail: hanna.tolli@bbs-artebone.fi

Certified Advisors:

First North Finland: Aalto Capital Partners Oy, tel. +358 40 5477 000

First North Sweden: Stockholm Certified Advisers AB, tel. +46 70 5516 729

BBS-Bioactive Bone Substitutes Plc  ("BBS") is the health technology company operating since  2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things.  We have over 20 years of expertise in this. Our operations are characterised by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA.  More information: www.bbs-artebone.fi .

DISTRIBUTION
Nasdaq Helsinki Ltd
Nasdaq Stockholm Ltd



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BBS-Bioactive Bone Substitutes Oyj via GlobeNewswire
HUG#2170791
GlobeNewswire
globenewswire.com

Last updated on: 22/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.